Macro­Gen­ics ear­marks $580M for ADC tech; Do­mainex, non­prof­it team up on Parkin­son's pro­gram

Synaf­fix and Macro­Gen­ics have signed a deal to code­vel­op and com­mer­cial­ize a clin­i­cal plat­form for an­ti­body-drug con­ju­gates to fight can­cer. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.